Healgen™ SARS-CoV-2/Flu A+B Rapid Antigen Test
Healgen Rapid Check SARS-CoV-2/Flu A+B Rapid Antigen Point-of-Care Test is a lateral flow immunoassay intended for in vitro rapid, simultaneous qualitative detection and differentiation of nucleocapsid antigen from SARS-CoV-2, influenza A and influenza B directly from anterior nasal swab specimens obtained from patients who are suspected of COVID-19 by their healthcare provider, within the first five days of onset of symptoms.
Variants (1)
- Default Title — 111.25 USD — In stock
AI Readiness
Good foundation, but some important product data is still missing.
75%